Vanguard Global Advisers
CUE icon

Vanguard Global Advisers’s Cue Biopharma CUE Stock Holding History

Vanguard Global Advisers’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.7K Buy
1,637
+1,204
+278% +$27.2K ﹤0.01% 3049
2026
Q1 		$2.99K Buy
+433
New +$4.04K ﹤0.01% 3597

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

Vanguard Global Advisers's CUE Position: Q2 2026 in Review

Vanguard Global Advisers increased its Cue Biopharma (CUE) stake by 278% in Q2 2026, buying an estimated $27.2K and bringing the position to 1,637 shares worth $51.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3049.

Vanguard Global Advisers first reported a position in CUE in Q1 2026 and has held it in 2 quarters since. 46 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Vanguard Global Advisers held 1,637 shares of Cue Biopharma worth $51.7K as of Q2 2026.
  • Vanguard Global Advisers bought 1,204 Cue Biopharma shares in Q2 2026, an estimated $27.2K.
  • Cue Biopharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3049 holding.
  • Vanguard Global Advisers first reported a position in Cue Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 46 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.